Stocks Health care MIRM
NASDAQ · Health careMirum Pharmaceuticals, Inc. (MIRM)
Mirum Pharmaceuticals, Inc. brought in $670.8M of revenue over the twelve months to September 30, 2026, up 42.2% from a year earlier. It posted a net loss of $903.9M. Operating cash flow minus capital spending left $54.9M of free cash flow in fiscal 2025. At September 30, 2026 it held $243.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about Mirum Pharmaceuticals, Inc.
- Net worth
- Mirum Pharmaceuticals, Inc. has a market value (market cap) of $6.1B at the latest share price, and shareholders' equity of -$54.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $521.3M (+54.7% year on year), with a net loss of $23.4M. Over the 12 months to September 30, 2026: revenue $670.8M, net loss $903.9M.
- Cash flow
- In fiscal 2025 operations brought in $55.8M of cash; after $954K of capital spending, free cash flow was $54.9M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Mirum Pharmaceuticals, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Mirum Pharmaceuticals, Inc. does
Mirum Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MIRM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $521.3M | -$23.4M | -$0.47 | $54.9M |
| 2024 | $336.9M | -$87.9M | -$1.85 | $9.3M |
| 2023 | $186.4M | -$163.4M | -$4.00 | -$71.1M |
| 2022 | $77.1M | -$135.7M | -$4.02 | -$120.4M |
| 2021 | $19.1M | -$84M | -$2.77 | -$132.8M |
| 2020 | $0 | -$103.3M | -$4.09 | -$89.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where MIRM ranks in Health care
Latest SEC filings
What Mirum Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 40% to $185.7M versus the same quarter last year; diluted EPS -$0.87 versus $0.05.
- November 3, 2026
- October 26, 2026Other event 8-K
- October 13, 2026Other event 8-K
- September 28, 2026Other event 8-K
- September 8, 2026
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 38% to $176.2M versus the same quarter last year; diluted EPS -$1.06 versus -$0.12.
- August 5, 2026
What is MIRM worth? A DCF from its reported cash flow
Insider trades
What the people running Mirum Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $9.8M worth of shares in the last 90 days and bought none on the open market. 49% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 4, 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER, Director | Exercised options | 20,000 | $58.7K |
| November 4, 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER, Director | Soldpre-planned (10b5-1) | 20,000 | $1.8M |
| October 16, 2026 | Howe JolandaSVP, GLOBAL CONTROLLER | Exercised options | 16,112 | $310K |
| October 6, 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER, Director | Exercised options | 5,305 | $101.8K |
| October 6, 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER, Director | Exercised options | 6,892 | $109.4K |
| September 14, 2026 | Bjerkholt EricCHIEF FINANCIAL OFFICER | Sold | 9,943 | $978.1K |
| September 11, 2026 | Bjerkholt EricCHIEF FINANCIAL OFFICER | Exercised options | 18,333 | - |
| September 2, 2026 | Howe JolandaSVP, GLOBAL CONTROLLER | Soldpre-planned (10b5-1) | 658 | $65.8K |
Who owns MIRM
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| JANUS HENDERSON GROUP Ltd.13G, passive | 9.7% | August 13, 2026 |
| Patrick J. Heron13D, may seek influence with 16 related filers | 6.8% | January 27, 2026 |
| Fmr LLC13G, passive with 1 related filers | 6.2% | August 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 327 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 7,679,684 | 0 |
| Jupiter Topco LLC | 5,909,184 | new |
| BlackRock, Inc. | 4,390,063 | +543,533 |
| Fmr LLC | 3,670,314 | +1,704,939 |
| Vanguard Portfolio Management LLC | 2,377,019 | +944,936 |
| Vanguard Capital Management LLC | 2,254,109 | -160,667 |
| State Street Corp | 2,170,689 | +226,408 |
| William Blair Investment Management, LLC | 1,404,741 | +1,069,072 |
| Geode Capital Management, LLC | 1,393,908 | +133,905 |
| Invesco Ltd. | 1,364,084 | +1,078,848 |
| Wellington Management Group Llp | 1,309,987 | -24,822 |
| Eventide Asset Management, LLC | 1,248,389 | -160,482 |
| Tang Capital Management LLC | 1,236,027 | 0 |
| Capital World Investors | 1,153,480 | +429,065 |
| Franklin Resources Inc | 1,152,770 | +437,966 |
| Novo Holdings A/S | 1,125,000 | -200,000 |
| TCG Crossover Management, LLC | 1,062,049 | 0 |
| Bvf Inc | 1,056,027 | -528,700 |
| Polar Capital Holdings Plc | 845,524 | +562,040 |
| Rock Springs Capital Management LP | 798,145 | -13,149 |
Insiders
9 insiders reported holding 1,020,831 shares in total, about $96.4M at the last price.
| Holder | Shares |
|---|---|
| Heron Patrick JDirector | 459,010459,010 held indirectly |
| Peetz ChristopherCHIEF EXECUTIVE OFFICER, Director | 394,137187,500 held indirectly |
| Radovich PeterPRESIDENT AND COO | 57,260 |
| Bjerkholt EricCHIEF FINANCIAL OFFICER | 44,745 |
| Quan JoanneCHIEF MEDICAL OFFICER | 18,864 |
| Howe JolandaSVP, GLOBAL CONTROLLER | 16,728 |
| Fischer LaurentDirector | 10,727 |
| Walbert Timothy PDirector | 9,680 |
| Cardon LonDirector | 9,680 |
Questions about MIRM
What does Mirum Pharmaceuticals, Inc. do?
Mirum Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as MIRM. Its shares trade on NASDAQ under the ticker MIRM.
What is Mirum Pharmaceuticals, Inc.'s net worth?
Mirum Pharmaceuticals, Inc. has a market value (market cap) of $6.1B at the latest share price, and shareholders' equity of -$54.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Mirum Pharmaceuticals, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $903.9M on revenue of $670.8M.
How much revenue does Mirum Pharmaceuticals, Inc. make?
Over the twelve months to September 30, 2026 Mirum Pharmaceuticals, Inc. reported revenue of $670.8M. That is 42.2% more than a year earlier.
When did Mirum Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 4, 2026.
When is Mirum Pharmaceuticals, Inc.'s next earnings report?
Mirum Pharmaceuticals, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare MIRM with
Follow MIRM
Get an email when Mirum Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Mirum Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.